Intas Pharmaceuticals Shows Double-Digit Growth Across India

Ahmedabad-based Intas Pharmaceuticals has reinforced its position as a leading player in the Indian Pharmaceutical Market (IPM), maintaining the 6th rank for both September 2025 and the Moving Annual Turnover (MAT) period.

The company reported remarkable double-digit growth in monthly and annual measures, reflecting a robust strategy to capture and retain market value across India’s diverse healthcare sector.

In September 2025, Intas Pharma achieved a monthly growth of 10.89%, well above the industry average, translating into gross sales of Rs. 805.54 crore and securing a 3.75% share of the monthly market.

Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery

The MAT performance further validates its sustained growth, with total annual sales exceeding Rs. 8,973 crore and a growth rate of 10.04%, signaling the company’s strong footing in the competitive IPM landscape.

The company’s EVOL factor of 102.09 highlights that its growth slightly outpaced the overall market expansion. A steady MAT market share of 3.70% indicates consistent demand and effective commercial execution across its product portfolio.

Geographically, northern markets were key growth drivers, with Delhi leading at 19% growth, followed by Uttarakhand at 17% and Rajasthan at 15%. Eastern markets like West Bengal and Kolkata also delivered solid double-digit expansion, while the southern Chennai market saw a 5% decline, highlighting areas for strategic focus.

Therapeutically, brands such as Neukine and Zoryl-M contributed strongly, with Neukine’s sales up 28% and Zoryl-M rising 11%. This momentum positions Intas Pharmaceuticals to sustain double-digit growth and potentially climb higher in IPM rankings in upcoming fiscal periods.